Finanzen von Eledon Pharmaceuticals Inc (ELDN)ELDNEledon Pharmaceuticals Inc

Evaluating the bottom line, Eledon Pharmaceuticals Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -236.51%, provide a clear picture of how effectively ELDN converts its operational activities into shareholder value.

In the context of the broader market, ELDN competes directly with industry leaders such as ACIU and SLGL. With a market capitalization of $219.40M, it holds a significant position in the sector. When comparing efficiency, ELDN's gross margin of N/A stands against ACIU's 100.00% and SLGL's 100.00%. Such benchmarking helps identify whether Eledon Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.

Eledon Pharmaceuticals has a forward P/E ratio of 5.39, indicating that it may be undervalued compared to its future earnings potential. The company has also seen a significant increase in hedge fund buying activity, up 138.83% over the last quarter, which suggests growing institutional interest.